PHOTOBIOMODULATION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Photobiomodulation Market, By Application (Pain Management, Wound Healing, Dermatology, Orthopedics, and Other Applications), By Wavelength (Infrared Light, Red Light, and Other Wavelengths), By Type of Device (Low-Level Laser Therapy (LLLT) Devices, Light Emitting Diode (LED) Devices, and Other Devices), By End User (Hospitals, Clinics, Home Care Settings, Research Institutes, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In August 2024, LumiThera,, a leader in photobiomodulation (PBM) treatments for eye conditions, announced the approval of a new Category III CPT code for photobiomodulation (PBM) therapy in retinal disease, effective January 2025. This milestone is supported by the LIGHTSITE III clinical trial, which demonstrated significant vision improvements and reduced disease progression in dry age-related macular degeneration (AMD) patients using the Valeda PBM system. With over 80% patient compliance and sustained benefits observed over 21 months, this development marks a crucial step toward wider access and reimbursement for non-invasive PBM treatments.
In January 2024, Iridex Corporation, a medical instrument manufacturing company, introduced two next-generation laser platforms, the Iridex 532 nm and Iridex 577 nm. These lasers utilize Iridex’s patented technology for laser delivery, designed to regulate photothermal effects during laser photocoagulation by allowing tissue to cool between pulses, thereby reducing or preventing potential tissue damage.
In January 2024, PhotoMedex, a leading provider of advanced light-based therapies,entered into a strategic partnership with Zimmer Biomet, a global leader in the orthopedic medical device industry, to develop and commercialize photobiostimulation devices specifically designed for orthopedic applications